The Omalizumab Biosimilars Market focuses on biosimilar versions of omalizumab, a monoclonal antibody that targets immunoglobulin E (IgE). Originator omalizumab has been used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by reducing free IgE and attenuating the allergic cascade. As patents expire and biosimilar pathways mature, omalizumab biosimilars are poised...
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek